18th IBD Intensive Advanced Course |
||
08:00-08:15 | Arrival and distribution of voting pads | |
08:15–08:30 | 1: Welcome & Introduction from the course director Silvio Danese, Milan, Italy James Lindsay, London, United Kingdom Pascal Juillerat, Bern, Switzerland |
|
08:30–10:30 | Session 1: Introduction and case-based management on conventional IBD Therapies Lead discussant: Axel Dignass, Frankfurt, Germany |
|
08:30-09:00 | 2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics Iris Dotan, Petah Tikva, Israel |
|
09:00-09:20 | 3: 5-ASA compounds Henit Yanai, Petah Tikva, Israel |
|
09:20-09:40 |
4: Thiopurines Peter M. Irving, London, United Kingdom |
|
09:40-10:00 |
5: Methotrexate Pascal Juillerat, Bern, Switzerland |
|
10:00-10:20 | 6: Steroids Konstantinos Katsanos, Ioannina, Greece |
|
10:20-10:30 | Discussion | |
10:30-10:50 | Coffee break | |
10:50-12:30 | Session 2: Case-based management of conventional IBD therapies Lead discussant: James Lindsay, London, United Kingdom |
|
10:50-11:10 | 7: Anti-TNF agents Pierre Michetti, Lausanne, Switzerland |
|
11:10-11:30 | 8: Anti-integrins James Lindsay, London, United Kingdom |
|
11:30-11:50 | 9: Ustekinumab Severine Vermeire, Leuven, Belgium |
|
11:50-12:10 | 10: Tofacitinib Florian Rieder, Cleveland, United States |
|
12:10-12:30 | 11: Small molecules and biologics in the pipeline Laurent Peyrin Biroulet, Vandoeuvre-les-Nancy, France |
|
12:30–14:00 | Lunch break | |
14:00-15:30 | Session 3: Round tables - 7 Themes/clinical cases discussion |
|
14:00-15:30 | 12a: Pregnancy Janneke Christien van der Woude, Rotterdam, The Netherlands Iris Dotan, Petah Tikva, Israel 12b: Extraintestinal manifestations Konstantinos Katsanos, Ioannina, Greece Péter L. Lakatos, Budapest, Hungary; Montreal, Canada 12c: When and how to stop biologics? Axel Dignass, Frankfurt, Germany Gerassimos Mantzaris, Athens, Greece 12d: Complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Yehuda Chowers, Haifa, Israel 12e: Therapeutic Drug Monitoring Pascal Juillerat, Bern, Switzerland Filip J. Baert, Roeselare, Belgium 12f: Exit strategy Marc Ferrante, Leuven, Belgium Joana Tinoco da Silva Torres, Lisbon, Portugal 12g: Therapeutic Endoscopy in IBD Pierre Michetti, Lausanne, Switzerland Henit Yanai, Petah Tikva, Israel |
|
15:30-15:50 | Coffee break | |
15:50-17:00 | Session 3: Round tables - 7 Themes/clinical cases discussion |
|
15:50-17:00 | 12a: Pregnancy Janneke Christien van der Woude, Rotterdam, The Netherlands Iris Dotan, Petah Tikva, Israel 12b: Extraintestinal manifestations Konstantinos Katsanos, Ioannina, Greece Péter L. Lakatos, Budapest, Hungary; Montreal, Canada 12c: When and how to stop biologics? Axel Dignass, Frankfurt, Germany Gerassimos Mantzaris, Athens, Greece 12d: Complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Yehuda Chowers, Haifa, Israel 12e: Therapeutic Drug Monitoring Pascal Juillerat, Bern, Switzerland Filip J. Baert, Roeselare, Belgium 12f: Exit strategy Marc Ferrante, Leuven, Belgium Joana Tinoco da Silva Torres, Lisbon, Portugal 12g: Therapeutic Endoscopy in IBD Pierre Michetti, Lausanne, Switzerland Henit Yanai, Petah Tikva, Israel |
18th IBD Intensive Advanced Course
Date | February 12-13, 2020 | |
Time | February 12 from 08:00 to 17:00 February 13 from 07:30 to 12:00 |
|
Responsible Committee | EduCom | |
Target audience | Junior gastroenterologists | |
Registration |
ECCO Membership 2020 required |
|
CME accreditation | 10 CME credits |
18th IBD Intensive Advanced Course
07:30-09:30
Session 4: Interactive case discussions
Lead discussants:
Pascal Juillerat, Bern, Switzerland
Antonio López-Sanromán, Madrid, Spain
07:30-08:00
13: Investigation and management of early Mild/Moderate Crohn's Disease
Case presentation: Timothy Raine, Cambridge, United Kingdom
Discussion: Laurence Egan, Galway, Ireland
08:00-08:05
Discussion
08:05–08:40
14: Management of perianal CD
Antonio López-Sanromán, Madrid, Spain
Paulo Gustavo Kotze, Curitiba, Brazil
08:40-08:45
Discussion
08:45-09:30
15: Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agents
Case presentation: Dominik Bettenworth, Münster, Germany
Discussion: Pascal Juillerat, Bern, Switzerland
Paulo G. Kotze, Curitiba, Brazil
09:30-09:45
Coffee break
09:45-11:45
Session 5: Special case scenarios
Lead discussant: Gerassimos Mantzaris, Athens, Greece
09:45–10:15
16: Management of refractory pouchitis
Iris Dotan, Petah Tikva, Israel
10:15-10:45
17: Management of Acute Severe Ulcerative Colitis
David Laharie, Bordeaux, France
10:45-11:15
18: Pre- and postoperative management of Crohn's Disease
Glen Doherty, Dublin, Ireland
11:15-11:45
Discussion
11:45-12:00
19: Feedback & Closing remarks
Pascal Juillerat, Bern, Switzerland